Compare · AZN vs DERM
AZN vs DERM
Side-by-side comparison of AstraZeneca PLC (AZN) and Journey Medical Corporation (DERM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and DERM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $245.79B, about 1388.3x DERM ($177.0M).
- Over the past year, AZN is down 16.5% and DERM is down 9.1% - DERM leads by 7.4 points.
- AZN has been more active in the news (13 items in the past 4 weeks vs 4 for DERM).
- AZN has more recent analyst coverage (25 ratings vs 7 for DERM).
- Company
- AstraZeneca PLC
- Journey Medical Corporation
- Price
- $157.22-0.77%
- $6.61+3.77%
- Market cap
- $245.79B
- $177.0M
- 1M return
- -6.54%
- -9.02%
- 1Y return
- -16.50%
- -9.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 13
- 4
- Recent ratings
- 25
- 7
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Journey Medical Corporation
Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Latest AZN
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
- SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
- AstraZeneca results: H1 and Q2 2026
Latest DERM
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Journey Medical Corporation
- Director Toledano Miranda Jayne was granted 50,000 shares, increasing direct ownership by 42% to 168,618 units (SEC Form 4)
- Director Smith Justin Adam was granted 50,000 shares, increasing direct ownership by 28% to 231,618 units (SEC Form 4)
- Director Herskowitz Neil was granted 50,000 shares, increasing direct ownership by 42% to 168,618 units (SEC Form 4)
- Director Toledano Miranda Jayne was granted 10,000 shares, increasing direct ownership by 9% to 118,618 units (SEC Form 4)
- Director Smith Justin Adam was granted 10,000 shares, increasing direct ownership by 6% to 181,618 units (SEC Form 4)